Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

A biosimilar is a closely engineered copy of an FDA-approved biologic. Unlike generic versions of drugs, biosimilars are not identical to the brand-name biologic they are duplicating. This is ...

Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global ...

Welcome to the latest issue of Blockbuster Biologics Review, which covers the status and developments of post-grant challenges and patent ...

Indian biosimilars developer Biocon Biologics, a subsidiary of Biocon Ltd (BSE: 532520, today announced that the UK’s ...

Samsung Biologics separates CDMO and biosimilars with new holding company Samsung Bioepis Holdings aims to enhance corporate ...

Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into ...

South Korean Samsung Group’s biopharmaceutical business is being reorganized into two separate tracks: contract development ...

Health experts discuss advanced biologic therapies in breast cancer treatment at a recent symposium in Hà Nội.